Evidence map›Paper›PMID 35836859›Full record

ArticleAmerican journal of translational research2022

Serum CHI3L1 as a diagnostic marker and risk factor for liver fibrosis in HBeAg-negative chronic hepatitis B.

Yuecui Li, Chenghang Li, Lili Zhang, Weiyue Hu, Hongxia Luo, Jin Li, Shuai Qiu, Shengwei Zhu

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yuecui LiDepartment of Infection Diseases, The First People's Hospital of Yongkang Yongkang 321300, Zhejiang, China.
Chenghang LiDepartment of Infection Diseases, The First People's Hospital of Yongkang Yongkang 321300, Zhejiang, China.
Lili ZhangDepartment of Infection Diseases, The First People's Hospital of Yongkang Yongkang 321300, Zhejiang, China.
Weiyue HuDepartment of Infection Diseases, The First People's Hospital of Yongkang Yongkang 321300, Zhejiang, China.
Hongxia LuoDepartment of Infection Diseases, The First People's Hospital of Yongkang Yongkang 321300, Zhejiang, China.
Jin LiDepartment of Infection Diseases, The First People's Hospital of Yongkang Yongkang 321300, Zhejiang, China.
Shuai QiuDepartment of Infection Diseases, The First People's Hospital of Yongkang Yongkang 321300, Zhejiang, China.
Shengwei ZhuDepartment of Infection Diseases, The First People's Hospital of Yongkang Yongkang 321300, Zhejiang, China.
Zhejiang Yongning Pharma (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hepatitis B (CHB) as the major inducement of hepatocellular carcinoma and cirrhosis, imposes a heavy health burden upon patients. This research aims to investigate the diagnostic value of serum chitinase 3-like 1 (CHI3L1) in hepatitis B e antigen (HBeAg)-negative CHB liver fibrosis (LF) and to analyze the risk factors. We selected 78 patients with HBeAg-negative CHB admitted to our hospital between October 2018 and October 2019, and grouped them (F

Indexed as

CHI3L1chronic hepatitis BdiagnosisHBeAgliver fibrosis

Identifiers

PMID35836859
PMCPMC9274598
OpenAlexW4285612538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.